Inner Mongolia Furui Med Sci
Inner Mongolia Furui Medical Science Co., Ltd. engages in the production and sale of pharmaceutical drugs in China and internationally. The company operates in two segments: pharmaceutical production and sales; and diagnostic equipment R&D, production and sales. The pharmaceutical production and sales segment produces and sells products, such as Fufang Biejiaruangan tablets and shell fat capsules… Read more
Inner Mongolia Furui Med Sci (300049) - Total Assets
Latest total assets as of September 2025: CN¥3.21 Billion CNY
Based on the latest financial reports, Inner Mongolia Furui Med Sci (300049) holds total assets worth CN¥3.21 Billion CNY as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Inner Mongolia Furui Med Sci - Total Assets Trend (2006–2024)
This chart illustrates how Inner Mongolia Furui Med Sci’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Inner Mongolia Furui Med Sci - Asset Composition Analysis
Current Asset Composition (December 2024)
Inner Mongolia Furui Med Sci's total assets of CN¥3.21 Billion consist of 49.8% current assets and 50.2% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 18.5% |
| Accounts Receivable | CN¥567.40 Million | 18.6% |
| Inventory | CN¥140.84 Million | 4.6% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥558.15 Million | 18.3% |
| Goodwill | CN¥205.09 Million | 6.7% |
Asset Composition Trend (2006–2024)
This chart illustrates how Inner Mongolia Furui Med Sci's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Inner Mongolia Furui Med Sci's current assets represent 49.8% of total assets in 2024, an increase from 47.6% in 2006.
- Cash Position: Cash and equivalents constituted 18.5% of total assets in 2024, up from 17.1% in 2006.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 24.0% of total assets, an increase from 10.0% in 2006.
- Asset Diversification: The largest asset category is accounts receivable at 18.6% of total assets.
Inner Mongolia Furui Med Sci Competitors by Total Assets
Key competitors of Inner Mongolia Furui Med Sci based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
ESSA Pharma Inc
NASDAQ:EPIX
|
USA | $110.50 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Inner Mongolia Furui Med Sci - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - Inner Mongolia Furui Med Sci generates 0.44x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Moderate ROA - For every $100 in assets, Inner Mongolia Furui Med Sci generates $ 3.70 in net profit.
Inner Mongolia Furui Med Sci - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 5.00 | 3.88 | 4.20 |
| Quick Ratio | 4.51 | 3.52 | 3.75 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥1.27 Billion | CN¥ 978.98 Million | CN¥ 743.23 Million |
Inner Mongolia Furui Med Sci - Advanced Valuation Insights
This section examines the relationship between Inner Mongolia Furui Med Sci's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 9.24 |
| Latest Market Cap to Assets Ratio | 0.50 |
| Asset Growth Rate (YoY) | 15.5% |
| Total Assets | CN¥3.06 Billion |
| Market Capitalization | $1.52 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Inner Mongolia Furui Med Sci's assets below their book value (0.50 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Inner Mongolia Furui Med Sci's assets grew by 15.5% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Inner Mongolia Furui Med Sci (2006–2024)
The table below shows the annual total assets of Inner Mongolia Furui Med Sci from 2006 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥3.06 Billion | +15.54% |
| 2023-12-31 | CN¥2.65 Billion | +4.94% |
| 2022-12-31 | CN¥2.52 Billion | -0.08% |
| 2021-12-31 | CN¥2.52 Billion | +10.22% |
| 2020-12-31 | CN¥2.29 Billion | +1.79% |
| 2019-12-31 | CN¥2.25 Billion | +5.44% |
| 2018-12-31 | CN¥2.13 Billion | -14.72% |
| 2017-12-31 | CN¥2.50 Billion | +3.99% |
| 2016-12-31 | CN¥2.41 Billion | +17.92% |
| 2015-12-31 | CN¥2.04 Billion | +53.32% |
| 2014-12-31 | CN¥1.33 Billion | +16.59% |
| 2013-12-31 | CN¥1.14 Billion | +23.09% |
| 2012-12-31 | CN¥927.58 Million | +6.14% |
| 2011-12-31 | CN¥873.89 Million | +9.83% |
| 2010-12-31 | CN¥795.66 Million | +217.04% |
| 2009-12-31 | CN¥250.96 Million | +12.49% |
| 2008-12-31 | CN¥223.10 Million | +11.03% |
| 2007-12-31 | CN¥200.93 Million | +6.99% |
| 2006-12-31 | CN¥187.80 Million | -- |